Marinus Pharmaceuticals (MRNS) versus Juniper Pharmaceuticals (JNP) Head-To-Head Contrast
Marinus Pharmaceuticals (NASDAQ: MRNS) and Juniper Pharmaceuticals (NASDAQ:JNP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.
Valuation and Earnings
This table compares Marinus Pharmaceuticals and Juniper Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Marinus Pharmaceuticals||N/A||N/A||-$28.64 million||($0.93)||-7.95|
|Juniper Pharmaceuticals||$54.57 million||1.01||$5.95 million||$0.59||8.64|
Volatility and Risk
Marinus Pharmaceuticals has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500. Comparatively, Juniper Pharmaceuticals has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500.
Insider and Institutional Ownership
49.8% of Marinus Pharmaceuticals shares are owned by institutional investors. Comparatively, 36.4% of Juniper Pharmaceuticals shares are owned by institutional investors. 6.4% of Marinus Pharmaceuticals shares are owned by insiders. Comparatively, 7.2% of Juniper Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Marinus Pharmaceuticals and Juniper Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and target prices for Marinus Pharmaceuticals and Juniper Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Marinus Pharmaceuticals currently has a consensus target price of $11.00, suggesting a potential upside of 48.85%. Juniper Pharmaceuticals has a consensus target price of $23.00, suggesting a potential upside of 350.98%. Given Juniper Pharmaceuticals’ higher possible upside, analysts plainly believe Juniper Pharmaceuticals is more favorable than Marinus Pharmaceuticals.
Juniper Pharmaceuticals beats Marinus Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.
Receive News & Ratings for Marinus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.